Eledon Pharmaceuticals, Inc. ELDN

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Eledon is a clinical stage biotechnology company using our immunology expertise in targeting the CD40 Ligand ("CD40L") pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis ("ALS"). Our lead compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that we believe has broad therapeutic potential. We believe the central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention.

Tegoprubart is engineered to potentially both improve safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation. CD40L is primarily expressed on activated CD4+ T cells, platelets and endothelial cells while the CD40 receptor is constitutively expressed on antigen presenting cells such as macrophages and dendritic cells, as well as B cells. By blocking CD40L and not the CD40 receptor, tegoprubart inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches. Blocking CD40L also increases polarization of CD4+ lymphocytes to Tregs, a specialized subpopulation of T cells that act to suppress an immune response, thus creating a more tolerogenic environment, which may play a therapeutic role in autoimmune diseases and in the prevention of allograft rejection after solid organ transplantation.

Last close 2.30 2026-10-23
Market cap $186.9M 2026-06-30 share count
52-week range 1.35 - 4.60

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.52

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue —————————$0
R&D $66.3M$52.0M$30.3M$27.1M$23.7M$6.1M$8.1M$6.8M$2.0M$3.2M
SG&A $17.0M$18.6M$12.7M$12.7M$13.1M$10.1M$6.1M$7.2M$11.1M$1.9M
Total operating expenses $83.3M$70.6M$43.0M$88.4M$36.9M$18.5M$16.1M$14.1M$13.1M$5.1M
Operating income ——-$43.0M-$88.4M-$36.9M-$18.5M-$16.1M-$14.1M-$13.1M-$5.1M
Pre-tax income -$45.6M-$35.8M-$116.5M-$88.0M-$36.9M-$23.2M-$16.0M-$14.1M-$13.1M-$5.7M
Income tax $35.0K$431.0K$0$0$2.4M$404.0K———$0
Net income -$45.6M-$36.2M-$116.5M-$88.0M-$34.5M-$22.8M-$16.0M-$14.1M-$13.1M-$5.7M
EPS, basic -0.52-0.66-4.73-6.16-2.33—————
EPS, diluted -0.52-0.66-4.73-6.16-2.33-15.72-24.42-1.56-2.30-2.46
Shares, diluted (wtd. avg.) 81.8M48.5M24.6M14.3M14.8M—————

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $22.8M$20.5M$4.6M$56.4M$84.8M$114.2M$8.8M$13.0M$17.3M$1.1M
Short-term investments $110.5M$119.6M$46.5M$0——————
Total current assets $135.7M$143.7M$56.1M$59.5M$88.3M$115.6M$10.0M$14.3M$19.0M$1.1M
Property, plant and equipment ——————$5.0K$14.0K$25.0K$31.0K
Goodwill ——$0$0$48.6M$48.6M—$1.9M$1.9M—
Total assets $169.0M$177.4M$89.1M$92.8M$170.5M$197.2M$10.9M$17.0M$20.9M$1.2M
Accounts payable $3.6M$5.8M$967.0K$2.2M$1.8M$1.4M$329.0K$689.0K$418.0K$338.0K
Total current liabilities $18.3M$11.6M$3.9M$6.5M$4.4M$2.5M$1.3M$2.5M—$2.8M
Total liabilities $32.2M$59.3M$81.9M$8.6M$6.6M$6.6M$1.5M$2.5M$1.4M$3.9M
Retained earnings -$401.2M-$355.6M-$319.4M-$202.9M-$114.9M-$80.4M-$57.6M-$41.6M-$27.5M-$14.4M
Total equity $81.1M$62.4M-$48.5M$23.8M$164.0M$190.6M$9.5M$14.5M$19.5M-$2.7M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$62.3M-$47.3M-$39.5M-$28.4M-$28.9M-$15.2M-$13.9M-$11.9M-$14.9M-$4.9M
Depreciation and amortisation —————————$171.0K
Capital expenditure —————————$9.0K
Investing cash flow $10.8M-$70.3M-$45.3M——$11.0M——$23.3M$1.0K
Financing cash flow $53.8M$133.5M$33.0M—-$449.0K$109.6M$9.7M$7.6M$7.9M$2.9M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-197732.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -150M -100M -50M 0 Revenue, FY2016: 0 Net income, FY2016: -5.7M Net income, FY2017: -13.1M Net income, FY2018: -14.1M Net income, FY2019: -16M Net income, FY2020: -22.8M Net income, FY2021: -34.5M Net income, FY2022: -88M Net income, FY2023: -116.5M Net income, FY2024: -36.2M Net income, FY2025: -45.6M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $0 — — — — — — — — —
Gross profit — — — — — — — — — —
Net income -$5.7M -$13.1M -$14.1M -$16.0M -$22.8M -$34.5M -$88.0M -$116.5M -$36.2M -$45.6M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
  • Results announced Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Results announced Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%